Coronary artery disease| Volume 98, ISSUE 1, P63-65, July 01, 2006

Download started.


Baseline Achievement of Lipid Goals and Usage of Lipid Medications in Patients With Diabetes Mellitus (from the Veterans Affairs Diabetes Trial)

      The American Diabetes Association has established lipid goals for patients with diabetes. Although diabetic populations historically have poor low-density lipoprotein (LDL) cholesterol goal adherence, little is known about adherence to triglyceride and high-density lipoprotein (HDL) cholesterol goals. To determine the degree of lipid goal attainment among patients with diabetes, and to characterize the patterns of lipid medication use, we evaluated the baseline data from 1,742 enrollees of the national Veterans Affairs Diabetes Trial. Using current American Diabetes Association lipid guidelines, we calculated the proportion of participants achieving a LDL cholesterol level <100 mg/dl, triglyceride level <150 mg/dl, and HDL cholesterol level >40 mg/dl in men (>50 mg/dl in women). We also performed a descriptive analysis of the use of lipid medications in this population. The baseline LDL cholesterol level was 111 ± 63 mg/dl, triglyceride level was 213 ± 277 mg/dl, and HDL cholesterol was 36 ± 10 mg/dl. At enrollment, 44% of veterans met the LDL cholesterol goal, 58% met the triglyceride goal, and 16% met the HDL cholesterol goal, but only 6% met all 3 goals. Of the 1,742 enrollees, 2/3 were receiving lipid therapy, with statins (58%) the most commonly used drug. Combination lipid therapy was used by 11% of enrollees. Although the enrollees of the Veterans Affairs Diabetes Trial demonstrated better adherence to the American Diabetes Association’s LDL cholesterol goal than other diabetic populations recently studied, more aggressive and directed lipid medication use is needed to treat the overall lipid profile better.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abraira C.
        • Duckworth W.
        • McCarren M.
        • Emanuele N.
        • Arca D.
        • Reda D.
        • Henderson W.
        Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2.
        J Diabetes Complications. 2003; 17: 314-322
      1. Standards of medical care in diabetes.
        Diabetes Care. 2005; 28: S4-S36
        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
      2. Veterans Health Administration’s clinical practice guidelines for the management of dyslipidemia in primary care. Available at: Accessed December 1, 2005.

        • Coon P.
        • Zulkowski K.
        Adherence to American Diabetes Association standards of care by rural health care providers.
        Diabetes Care. 2002; 25: 2224-2229
        • Fuke D.
        • Hunt J.
        • Siemienczuk J.
        • Estoup M.
        • Carroll M.
        • Payne N.
        • Touchette D.
        Cholesterol management of patients with diabetes in a primary care practice-based research network.
        Am J Manag Care. 2004; 10: 130-136
        • Jacobs M.J.
        • Kleisli T.
        • Pio J.R.
        • Malik S.
        • L’Italien G.J.
        • Chen R.S.
        • Wong N.D.
        Prevalence and control of dyslipidemia among persons with diabetes in the United States.
        Diabetes Res Clin Pract. 2005; 70: 263-269
        • Snow V.
        • Aronson M.D.
        • Hornbake E.R.
        • Mottur-Pilson C.
        • Weiss K.B.
        Lipid control in the management of type 2 diabetes mellitus.
        Ann Intern Med. 2004; 140: 644-649
        • Verges B.
        Diabetic dyslipidaemia.
        Curr Med Res Opin. 2005; 21: S29-S40
        • Keech A.
        • Simes R.J.
        • Barter P.
        • Best J.
        • Scott R.
        • Taskinen M.R.
        • Forder P.
        • Pillai A.
        • Davis T.
        • Glasziou P.
        • et al.
        Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study).
        Lancet. 2005; 366: 1849-1861
        • Rubins H.B.
        • Robins S.J.
        • Collins D.
        • Nelson D.B.
        • Elam M.B.
        • Schaefer E.J.
        • Faas F.H.
        • Anderson J.W.
        Diabetes, plasma insulin, and cardiovascular disease.
        Arch Intern Med. 2002; 162: 2597-2604
        • Canner P.L.
        • Furberg C.D.
        • Terrin M.L.
        • McGovern M.E.
        Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
        Am J Cardiol. 2005; 95: 254-257